For decades, American culture has framed obesity as a failure of willpower. Eat less, move more, cut carbs. But that approach doesn’t work for everyone. Powerful new weight-loss drugs are shifting the conversation — away from blame and toward biology and long-term care.
GLP-1 (glucagon-like peptide-1) medications are reframing obesity not as a personal failing but as a complex condition shaped by genetics, hormones, sleep, stress, and environment.
“We’ve stigmatized patients with obesity,” says Sean Cahill, MD, an internist and pediatrician affiliated with Northwestern Medicine. “But this is about physiology, not laziness. We’re all inherently animals and wired to eat. Our genetics haven’t caught up to our reality.”
GLP-1 receptor agonists first gained approval for type 2 diabetes in 2005. Recent examples include semaglutide, marketed as Ozempic for diabetes and Wegovy for weight loss, and tirzepatide, marketed as Mounjaro and Zepbound. Today, these drugs help people lose an average of 20% of their body weight — results once thought possible only through surgery.